Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name	of entity	
Usco	om Ltd	
ABN 35 09	91 028 090	
We (t	the entity) give ASX the following	g information.
	t 1 - All issues ust complete the relevant sections (attac	h sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully paid ordinary shares Unquoted options
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	666,667 ordinary shares 222,222 unquoted options
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares Unquoted options exercisable at 25c on or before 31 July 2017

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Ordinary shares - yes

Unquoted options – no

Any ordinary shares issued upon exercise of options will rank equally with ordinary shares

5 Issue price or consideration

Fully paid ordinary shares issued at \$0.15

Unquoted options – nil, on the basis of one attaching option for every 3 shares issued under the placement

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) Private placement to Chesapeake Capital Limited as part of placement to professional and sophisticated investors – to fund the acquisition of Thor Laboratories KFT, integration of Thor Laboratories and for working capital. Refer Company announcement 23 July 2015.

6a Is the entity an+eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

Yes

6b The date the security holder resolution under rule 7.1A was passed

26 November 2014

6c Number of *securities issued without security holder approval under rule 7.1

666,667 shares

222,222 unquoted options

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of securities issued under an exception in rule 7.2	N/A	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Capacity under rule 7.1	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	31 July 2015	
8	Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable)	Number 92,330,326	⁺ Class Fully paid Ordinary Shares

⁺ See chapter 19 for defined terms.

9 Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)

Number	+Class
3,444,433	Options to acquire unissued ordinary shares exercisable at 25c expiry 31 July 2017
1,900,000	Employee Options to acquire unissued ordinary Shares
450,000	Performance Rights to acquire unissued ordinary Shares
5,409,902	Indeterminate Rights to acquire unissued ordinary Shares

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Not applicable

Part 2 - Bonus issue or pro rata issue

	N/A
required?	
Is the issue renounceable or non-renounceable?	N/A
_	
Ratio in which the *securities will be offered	N/A
_	
*Class of *securities to which the offer relates	N/A
_	
⁺ Record date to determine entitlements	N/A
_	
registers (or subregisters) be aggregated for calculating	N/A
	Is the issue renounceable or non-renounceable? Ratio in which the *securities will be offered *Class of *securities to which the offer relates *Record date to determine entitlements Will holdings on different registers (or subregisters) be

17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has *security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with.	N/A
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on *security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
20	Date rights trading will end (if	N/A
29	applicable)	11//1

⁺ See chapter 19 for defined terms.

30		do *security holders sell entitlements <i>in full</i> through er?	N/A
31		1	N/A
32	of the	lo ⁺ security holders dispose ir entitlements (except by crough a broker)?	N/A
33	⁺ Desp	atch date	N/A
You ne	ed only c		PS Oplying for quotation of securities
34	Type of tick of	of securities ne)	
(a)	X	Securities described in Part	1
(b)		-	nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible
Entit	ties th	at have ticked box 34	(a)
Addi	itional	securities forming a	new class of securities
	to indica nents	te you are providing the informa	ation or
35			securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36		*securities setting out the nu 1 - 1,000	v securities, a distribution schedule of the additional number of holders in the categories
		1,001 - 5,000 5,001 - 10,000	
		10,001 - 100,000 100,001 and over	

37	A copy of any trust deed for the additional *securities		
Entit	Entities that have ticked box 34(b)		
38	Number of securities for which ⁺ quotation is sought	N/A	
39	Class of *securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	N/A	
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)	N/A	
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)	Number N/A	⁺ Class N/A

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 14 August 2015

Company Secretary

Print name: Catherine Officer

Appendix 3B - Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	81,459,490	
Add the following: Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	Nil	
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid ordinary securities that became fully paid in that 12 month period		
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items		
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	Nil	
"A"	81,459,490	

⁺ See chapter 19 for defined terms.

Stop 2: Calculate 15% of "A"		
Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	12,218,923	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of equity securities issued or agreed to be issued in that 12 month	1,520,720 fully paid ordinary shares issued 23 July 2015 - placement	
• Under an exception in rule 7.2	3,222,211 unquoted options issued 23 July 2015 – placement	
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 	287,500 fully paid ordinary shares issued 31 July 2015	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	666,667 fully paid ordinary shares issued 14 August 2015 – placement 222,222 unquoted options issued 14 August 2015 - placement	
"C"	5,919,320	
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1	B"] to calculate remaining	
"A" x 0.15	12,218,923	
Note: number must be same as shown in Step 2		
Subtract "C"	5,030,431	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	6,299,603	
	[Note: this is the remaining placement capacity under rule 7.1]	

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" Note: number must be same as shown in Step 1 of Part 1	81,459,490	
Step 2: Calculate 10% of "A"		
"D"	0.10 Note: this value cannot be changed	
Multiply "A" by 0.10	8,145,949	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
 Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	8,145,949 issued 23 July 2015 - placement	
"E"	8.145,949	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10 Note: number must be same as shown in Step 2	8,145,949	
Subtract "E" Note: number must be same as shown in Step 3	8,145,949	
<i>Total</i> ["A" x 0.10] – "E"	Nil Note: this is the remaining placement capacity under rule 7.1A	